Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium

Author's Avatar
Aug 20, 2018
Article's Main Image
  • Military Health System provides healthcare to more than nine million people; the research symposium highlights scientific advancements that impact military medicine
  • Osteoarthritis is a leading cause of disability discharge from the military
  • Post-hoc analysis showed those treated with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) felt significant, sustained improvements in knee pain